An FDA reviewer battles the drug his boss approved: private letter gets Dr. Misbin pulled from diabetes case but he pursues it anyway.
Mathews
Anna Wilde
AW
D000063:Accidents, Traffic; D000682:Amyloid / Q000009:adverse effects* / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy*; D017277:Drug Approval; D004345:Drug Industry; D015507:Drugs, Investigational; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D058228:Islet Amyloid Polypeptide; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration; D035642:Whistleblowing
D000682:Amyloid; D015507:Drugs, Investigational; D058228:Islet Amyloid Polypeptide; C105254:pramlintide